臨床検査53巻13号

2009年12月発行

今月の主題 前立腺癌 総論

前立腺癌のアンドロゲン依存性とその消失

著者： 深堀能立¹ 本田幹彦¹ 神原常仁¹ 吉田謙一郎¹

所属機関： ¹獨協医科大学医学部泌尿器科

ページ範囲：P.1631 - P.1639

　前立腺癌のアンドロゲン依存性増殖とその逸脱機序については，近年次第に明らかになってきているものの，多種多様な機序が複雑に関連し合い，体系的理解が困難になりつつある．本稿では，前立腺癌組織内アンドロゲン動態やアンドロゲン受容体のnongenomic作用も踏まえた観点からこれらを整理・体系化し，前立腺癌のアンドロゲン依存性とその消失について概説した．

参考文献

1) Mohler JL：Castration-recurrent prostate cancer is not androgen-independent. Adv Exp Med Biol　617：223-234, 2008

2) Attard G, Reid AH, Yap TA, et al：Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol　26：4563-4571, 2008

3) Tran C, Ouk S, Clegg NJ, et al：Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science　324：787-790, 2009

4) Tomlins SA, Rhodes DR, Perner S, et al；Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science　310：644-648, 2005

5) McKeehan WL, Adams PS, Rosser MP：Direct mitogenic effects of insulin, epidermal growth factor, glucocorticoid, cholera toxin, unknown pituitary factors and possibly prolactin, but not androgen, on normal rat prostate epithelial cells in serum-free, primary cell culture. Cancer Res　44：1998-2010, 1984

6) Yan G, Fukabori Y, Nikolaropoulos S, et al：Heparin-binding keratinocyte growth factor is a candidate stromal-to-epithelial-cell andromedin. Mol Endocrinol　6：2123-2128, 1992

7) Sugimura Y, Cunha GR, Bigsby RM：Androgenic induction of DNA synthesis in prostatic glands induced in the urothelium of testicular feminized (Tfm/Y) mice. Prostate　9：217-225, 1986

8) Losel R, Wehling M：Nongenomic actions of steroid hormones. Nat Rev Mol Cell Biol　4：46-56, 2003

9) 深堀能立：前立腺のgrowth factor．臨床泌尿器科　55：595-610，2001

10) 深堀能立：アンドロロジーの最近の進歩 前立腺ホルモン支配の分子機構と細胞増殖因子．臨床泌尿器科　53：771-778，1999

11) Masuda H, Fukabori Y, Nakano K, et al：Expression of bone morphogenetic protein-7(BMP-7)in human prostate. Prostate　59：101-106, 2004

12) Liu XH, Wiley HS, Meikle AW：Androgens regulate proliferation of human prostate cancer cells in culture by increasing transforming growth factor-alpha (TGF-alpha) and epidermal growth factor (EGF)/TGF-alpha receptor. J Clin Endocrinol Metab　77：1472-1478, 1993

13) Sehgal I, Bailey J, Hitzemann K, et al：Epidermal growth factor receptor-dependent stimulation of amphiregulin expression in androgen-stimulated human prostate cancer cells. Mol Biol Cell　5：339-347, 1994

14) Payson RA, Chotani MA, Chiu IM：Regulation of a promoter of the fibroblast growth factor 1 gene in prostate and breast cancer cells. J Steroid Biochem Mol Biol　66：93-103, 1998

15) Xu Y, Chen SY, Ross KN, et al：Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins. Cancer Res　66：7783-7792, 2006

16) Ngan S, Stronach EA, Photiou A, et al：Microarray coupled to quantitative RT-PCR analysis of androgen-regulated genes in human LNCaP prostate cancer cells. Oncogene　28：2051-2063, 2009

17) Joseph IB, Isaacs JT：Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers. Cancer Res　57：1054-1057, 1997

18) Stewart RJ, Panigrahy D, Flynn E, et al：Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma：evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts. J Urol　165：688-693, 2001

19) Martin DB, Gifford DR, Wright ME, et al：Quantitative proteomic analysis of proteins released by neoplastic prostate epithelium. Cancer Res　64：347-355, 2004

20) Ravenna L, Lubrano C, Di-Silverio F, et al：Androgenic and antiandrogenic control on epidermal growth factor, epidermal growth factor receptor, and androgen receptor expression in human prostate cancer cell line LNCaP. Prostate　26：290-298, 1995

21) Qi W, Gao S, Wang Z：Transcriptional regulation of the TGF-beta1 promoter by androgen receptor. Biochem J　416：453-462, 2008

22) Itoh N, Patel U, Skinner MK：Developmental and hormonal regulation of transforming growth factor-alpha and epidermal growth factor receptor gene expression in isolated prostatic epithelial and stromal cells. Endocrinology　139：1369-1377, 1998

23) Nakano K, Fukabori Y, Itoh N, et al：Androgen-stimulated human prostate epithelial growth mediated by stromal-derived fibroblast growth factor-10. Endocr J　46：405-413, 1999

24) Le H, Arnold JT, McFann KK, et al：DHT and testosterone, but not DHEA or E2, differentially modulate IGF-I, IGFBP-2, and IGFBP-3 in human prostatic stromal cells. Am J Physiol Endocrinol Metab　290：E952-960, 2006

25) Chan JM, Stampfer MJ, Giovannucci E, et al：Plasma insulin-like growth factor-I and prostate cancer risk：a prospective study. Science　279：563-566, 1998

26) Tomlins SA, Laxman B, Dhanasekaran SM, et al：Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature　448：595-599, 2007

27) Rickman DS, Pflueger D, Moss B, et al：SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer. Cancer Res　69：2734-2738, 2009

28) Pflueger D, Rickman DS, Sboner A, et al：N-myc downstream regulated gene 1(NDRG1) is fused to ERG in prostate cancer. Neoplasia　11：804-811, 2009

29) 宮城洋平，佐々木毅，藤浪潔，他：Less frequent event of gene fusions involving ETS family transcription factors in Japanese prostate cancers(日本人前立腺癌におけるEtsファミリー関連融合遺伝子形成 日本人では欧米よりも頻度が低い)．日本癌学会総会記事　67：275，2008

30) Thomas LN, Douglas RC, Lazier CB, et al：Levels of 5alpha-reductase type 1 and type 2 are increased in localized high grade compared to low grade prostate cancer. J Urol　179：147-151, 2008

31) Thomas LN, Douglas RC, Lazier CB, et al：Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer. Eur Urol　53：244-252, 2008

32) Falkenstein E, Tillmann HC, Christ M, et al：Multiple actions of steroid hormones--a focus on rapid, nongenomic effects. Pharmacol Rev　52：513-556, 2000

33) Heinlein CA, Chang C：The roles of androgen receptors and androgen-binding proteins in nongenomic androgen actions. Mol Endocrinol　16：2181-2187, 2002

. J Clin Endocrinol Metab　90：893-903, 2005

35) Unni E, Sun S, Nan B, et al：Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence. Cancer Res　64：7156-7168, 2004

36) Craft N, Shostak Y, Carey M, et al：A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med　5：280-285, 1999

37) Matsuda T, Junicho A, Yamamoto T, et al：Cross-talk between signal transducer and activator of transcription 3 and androgen receptor signaling in prostate carcinoma cells. Biochem Biophys Res Commun　283：179-187, 2001

38) 小宮顕：アンドロゲン非依存性進展　アンドロゲンレセプターの変異．日本臨牀　65(増刊10)：79-85，2007

39) Chen CD, Welsbie DS, Tran C, et al：Molecular determinants of resistance to antiandrogen therapy. Nat Med　10：33-39, 2004

40) Miyoshi Y, Ishiguro H, Uemura H, et al：Expression of AR associated protein 55(ARA55) and androgen receptor in prostate cancer. Prostate　56：280-286, 2003

41) 上村博司，石黒斉，三好康秀，他：アンドロゲン非依存性進展　前立腺癌におけるAR cofactorの意義．日本臨牀　65(増刊10)：86-90，2007

42) Mohler JL, Gregory CW, Ford OH 3rd, et al：The androgen axis in recurrent prostate cancer. Clin Cancer Res　10：440-448, 2004

43) Titus MA, Schell MJ, Lih FB, et al：Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res　11：4653-4657, 2005

44) Nishiyama T, Hashimoto Y, Takahashi K：The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer. Clin Cancer Res　10：7121-7126, 2004

45) Stanbrough M, Bubley GJ, Ross K, et al：Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res　66：2815-2825, 2006

steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res　68：6407-6415, 2008

47) Bruno RD, Gover TD, Burger AM, et al：17alpha-Hydroxylase/17, 20 lyase inhibitor VN/124-1 inhibits growth of androgen-independent prostate cancer cells via induction of the endoplasmic reticulum stress response. Mol Cancer Ther　7：2828-2836, 2008

48) Uemura M, Tamura K, Chung S, et al：Novel 5 alpha-steroid reductase(SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer. Cancer Sci　99：81-86, 2008

49) Shah SK, Trump DL, Sartor O, et al：Phase II study of Dutasteride for recurrent prostate cancer during androgen deprivation therapy. J Urol　181：621-626, 2009

50) 深堀能立：ホルモン非依存性再燃機序．日本臨牀　58(増刊)：45-52，2000

. J Urol　169：281, 2003

52) Humphrey PA, Zhu X, Zarnegar R, et al：Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol　147：386-396, 1995

53) Ide H, Katoh M, Sasaki H, et al：Cloning of human bone morphogenetic protein type IB receptor (BMPR-IB) and its expression in prostate cancer in comparison with other BMPRs. Oncogene　14：1377-1382, 1997

54) Ide H, Yoshida T, Matsumoto N, et al：Growth regulation of human prostate cancer cells by bone morphogenetic protein-2. Cancer Res　57：5022-5027, 1997

55) McDonnell TJ, Troncoso P, Brisbay SM, et al：Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res　52：6940-6944, 1992

56) Leger JG, Montpetit ML, Tenniswood MP：Characterization and cloning of androgen-repressed mRNAs from rat ventral prostate. Biochem Biophys Res Commun　147：196-203, 1987

57) Miyake H, Nelson C, Rennie PS, et al：Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer. Cancer Res　60：170-176, 2000

58) Zegarra-Moro OL, Schmidt LJ, Huang H, et al：Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res　62：1008-1013, 2002

59) Jarrard DF, Kinoshita H, Shi Y, et al：Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells. Cancer Res　58：5310-5314, 1998

60) Yan G, Fukabori Y, McBride G, et al：Exon switching and activation of stromal and embryonic fibroblast growth factor (FGF)-FGF receptor genes in prostate epithelial cells accompany stromal independence and malignancy. Mol Cell Biol　13：4513-4522, 1993

61) Nasu Y, Timme TL, Yang G, et al：Suppression of caveolin expression induces androgen sensitivity in metastatic androgen-insensitive mouse prostate cancer cells. Nat Med　4：1062-1064, 1998

62) Ghosh PM, Malik SN, Bedolla RG, et al：Signal transduction pathways in androgen-dependent and-independent prostate cancer cell proliferation. Endocr Relat Cancer　12：119-134, 2005